



## HOOKIPA Pharma to Present at SVB Leerink's CybeRx Series Vaccine Forum

September 16, 2020

NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate and present at SVB Leerink's CybeRx Series: Vaccine Forum, taking place September 23 – 24, 2020:

- HOOKIPA Fireside Chat: Wednesday, **September 23<sup>rd</sup> at 12:00 PM ET** with Joern Aldag (CEO) and Igor Matushansky (CMO)

### About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that reprograms the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, non-replicating (VaxWave<sup>®</sup>) and replicating (TheraT<sup>®</sup>), induce robust antigen-specific CD8<sup>+</sup> T cells and pathogen-neutralizing antibodies. HOOKIPA's "off-the-shelf" viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8<sup>+</sup> T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA's non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.

Find out more about HOOKIPA online at [www.hookipapharma.com](http://www.hookipapharma.com).

For further information, please contact:

#### Media

Nina Waibel  
Senior Director - Communications  
[nina.waibel@hookipapharma.com](mailto:nina.waibel@hookipapharma.com)

#### Investors

Matt Beck  
Executive Director - Investor Relations  
[matthew.beck@hookipapharma.com](mailto:matthew.beck@hookipapharma.com)